J&J buys Aragon’s prostate cancer arm


Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.

Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.

J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.


Related Content

Genentech to buy breast cancer specialist Seragon

2 July 2014 Business

news image

$1.7bn deal for hormone receptor-destroying drug pipeline

Riding new waves

6 January 2015 Business

news image

Pharmaceutical industry roundup of 2014

Most Commented

New law on legal highs approved in UK

1 February 2016 News and Analysis

news image

A blanket ban on New Psychoactive Substances has been given final approval and will come into force in April

Beyond element 118: the next row of the periodic table

29 January 2016 News and Analysis

news image

A technological leap may be called for to expand the number of elements in existence